Company Performance - B&G Foods reported quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.14 per share, and down from $0.18 per share a year ago, representing an earnings surprise of -71.43% [1] - The company posted revenues of $425.4 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 7.72%, and down from $475.22 million year-over-year [2] - Over the last four quarters, B&G Foods has not surpassed consensus EPS estimates and has topped consensus revenue estimates only twice [2] Stock Performance - B&G Foods shares have declined approximately 8.4% since the beginning of the year, compared to a -4.7% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $435.7 million, and for the current fiscal year, it is $0.69 on revenues of $1.92 billion [7] Industry Outlook - The Zacks Industry Rank for Food - Miscellaneous is currently in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that industry outlook can significantly impact stock performance [5][8]

Company Performance - One Stop Systems, Inc. reported a quarterly loss of $0.07 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.04, marking an earnings surprise of -75% [1] - The company posted revenues of $12.26 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 3.47%, and down from $12.65 million a year ago [2] - Over the last four quarters, One Stop Systems has not surpassed consensus EPS estimates, and has only topped consensus revenue estimates three times [2] Stock Outlook - One Stop Systems shares have declined approximately 22.7% since the beginning of the year, compared to a decline of 4.7% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $13.8 million, and -$0.02 on revenues of $59.9 million for the current fiscal year [7] - The estimate revisions trend for One Stop Systems is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Electronics - Miscellaneous Products industry, to which One Stop Systems belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, suggesting a challenging environment [8] - Empirical research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than a factor of 2 to 1 [8]

Core Insights - Bloomin' Brands (BLMN) reported quarterly earnings of $0.59 per share, exceeding the Zacks Consensus Estimate of $0.57 per share, but down from $0.70 per share a year ago, indicating a 15.71% year-over-year decline [1] - The company achieved revenues of $1.05 billion for the quarter, surpassing the Zacks Consensus Estimate by 1.32%, but down from $1.2 billion year-over-year, reflecting a 12.5% decrease [2] - Bloomin' Brands has underperformed the market, with shares down approximately 35.1% year-to-date compared to the S&P 500's decline of 4.7% [3] Earnings Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [2] - The earnings surprise for the latest quarter was 3.51%, with no surprise in the previous quarter where actual earnings matched expectations [1][2] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.36 on revenues of $985.29 million, and for the current fiscal year, it is $1.28 on revenues of $3.91 billion [7] - The estimate revisions trend for Bloomin' Brands is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Retail - Restaurants industry, to which Bloomin' Brands belongs, is currently in the bottom 20% of the Zacks industry rankings, suggesting a challenging environment [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Bloomin' Brands' stock performance [5]

Company Performance - C4 Therapeutics reported a quarterly loss of $0.37 per share, better than the Zacks Consensus Estimate of a loss of $0.48, and an improvement from a loss of $0.41 per share a year ago, representing an earnings surprise of 22.92% [1] - The company posted revenues of $7.24 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 103.03%, compared to revenues of $3.04 million in the same quarter last year [2] - Over the last four quarters, C4 Therapeutics has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - C4 Therapeutics shares have declined approximately 60.8% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.44 on revenues of $7.25 million, and for the current fiscal year, it is -$1.74 on revenues of $22.72 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which C4 Therapeutics belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact C4 Therapeutics' stock performance [5]

Company Performance - Forge Global Holdings, Inc. reported a quarterly loss of $1.29 per share, which was better than the Zacks Consensus Estimate of a loss of $1.34, and an improvement from a loss of $1.50 per share a year ago, representing an earnings surprise of 3.73% [1] - The company posted revenues of $25.3 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.27%, and showing an increase from year-ago revenues of $19.24 million [2] - Over the last four quarters, Forge Global has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Forge Global shares have declined approximately 13.5% since the beginning of the year, compared to a decline of 4.7% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$1.03 on revenues of $23.22 million, and for the current fiscal year, it is -$4.27 on revenues of $98.57 million [7] Industry Outlook - The Financial - Miscellaneous Services industry, to which Forge Global belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Forge Global's stock performance [5]

Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items. What's Next for Apellis Pharmaceuticals? While Apellis Pharmaceuticals has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measu ...

分组1 - MarketAxess reported quarterly earnings of $1.87 per share, exceeding the Zacks Consensus Estimate of $1.82 per share, but down from $1.92 per share a year ago, representing an earnings surprise of 2.75% [1] - The company posted revenues of $208.58 million for the quarter, missing the Zacks Consensus Estimate by 0.97%, and down from $210.32 million year-over-year [2] - Over the last four quarters, MarketAxess has surpassed consensus EPS estimates four times but has only topped consensus revenue estimates once [2] 分组2 - The stock has gained approximately 1.3% since the beginning of the year, contrasting with the S&P 500's decline of 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is $1.91 on revenues of $214.96 million, and for the current fiscal year, it is $7.59 on revenues of $870.21 million [7] - The Zacks Industry Rank for Financial - Investment Bank is currently in the bottom 24% of over 250 Zacks industries, indicating potential challenges for the sector [8]

Company Performance - Turning Point Brands (TPB) reported quarterly earnings of $0.91 per share, exceeding the Zacks Consensus Estimate of $0.75 per share, and up from $0.80 per share a year ago, representing an earnings surprise of 21.33% [1] - The company posted revenues of $106.44 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 11.92%, compared to $97.06 million in the same quarter last year [2] - Over the last four quarters, Turning Point Brands has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Turning Point Brands shares have increased approximately 8% since the beginning of the year, while the S&P 500 has declined by 4.7% [3] - The current consensus EPS estimate for the upcoming quarter is $0.91 on revenues of $106.55 million, and for the current fiscal year, it is $3.42 on revenues of $425.4 million [7] Industry Outlook - The Tobacco industry, to which Turning Point Brands belongs, is currently ranked in the top 9% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.34 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 19.35%. A quarter ago, it was expected that this company would post earnings of $0.15 per share when it actually produced earnings of $0.14, delivering a surprise of -6.67%.Over the last four quar ...

Group 1: Earnings Performance - LifeStance Health Group (LFST) reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.04, and improved from a loss of $0.06 per share a year ago, representing an earnings surprise of 100% [1] - The company posted revenues of $332.97 million for the quarter ended March 2025, slightly missing the Zacks Consensus Estimate by 0.08%, compared to year-ago revenues of $300.44 million [2] - Over the last four quarters, LifeStance Health has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Group 2: Stock Performance and Outlook - LifeStance Health shares have declined approximately 11.1% since the beginning of the year, while the S&P 500 has decreased by 4.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.03 on revenues of $351.71 million, and -$0.10 on revenues of $1.42 billion for the current fiscal year [7] Group 3: Industry Context - The Medical - Outpatient and Home Healthcare industry, to which LifeStance Health belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that tracking these revisions can be beneficial for investors [5] - The favorable estimate revisions trend for LifeStance Health has resulted in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6]